Comparative Pharmacology
Head-to-head clinical analysis: MISOPROSTOL versus TRAVATAN Z.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MISOPROSTOL versus TRAVATAN Z.
MISOPROSTOL vs TRAVATAN Z
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Misoprostol is a synthetic prostaglandin E1 analog that induces uterine contractions and cervical ripening by binding to prostaglandin receptors, leading to increased intracellular calcium and myometrial contraction. It also inhibits gastric acid secretion by reducing parietal cell activity and protecting gastric mucosa via increased bicarbonate and mucus production.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
200 mcg orally four times daily (with meals and at bedtime) for prevention of NSAID-induced gastric ulcers; 800 mcg sublingually every 4 hours for up to 3 doses for labor induction; 25 mcg orally single dose for cervical ripening.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
None Documented
None Documented
Clinical Note
moderateTiaprofenic acid + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Misoprostol
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Mesalazine."
Clinical Note
moderateBalsalazide + Misoprostol
2-3 hours for misoprostol acid (active metabolite); clinically, a short duration requires multiple daily dosing. In patients with renal impairment, half-life may be prolonged but not significantly clinically.
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Primarily renal excretion of metabolites; ~80-90% of a radiolabeled dose is excreted in urine within 24 hours, with the remainder in feces. Misoprostol acid (active metabolite) undergoes further beta-oxidation and reduction; <1% excreted unchanged.
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Category D/X
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Misoprostol can be decreased when used in combination with Balsalazide."